CCL2 and diabetic kidney disease: Hyperoside, derived from C. pinnatifida, has shown reduced MCP-1 levels in HG-induced podocytes and mesangial cells, as well as in STZ-induced DKD rats, providing a basis for its use in DKD treatment (28).